Page 1 | Search Results | Blood Advances | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

Nausheen Ahmed, William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Jamie Brower, Gunjan L. Shah, Andy I. Chen, Olalekan O. Oluwole, Stephen J. Schuster, Michael R. Bishop, Joseph P. McGuirk, Peter A. Riedell

Blood Adv (2024) 8 (20): 5346–5354.

https://doi.org/10.1182/bloodadvances.2023012549

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL

Ibrahim Aldoss, Gregory W Roloff, Rawan G Faramand, Noam E. Kopmar, Chenyu Lin, Anjali S. Advani, Simone E. Dekker, Vishal K. Gupta, Timothy E. O'Connor, Nikeshan Jeyakumar, Ibrahim N. Muhsen, Yannis K. Valtis, Amy Zhang, Katharine Miller, Katherine C. Sutherland, Kaitlyn C. Dykes, Mohamed Ahmed, Evan C. Chen, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc S. Schwartz, Sean I Tracy, Bhagirathbhai Dholaria, Michal Jakub Kubiak, Akash Mukherjee, Navneet S Majhail, Minoo Battiwalla, Luke Mountjoy, Shahbaz A. Malik, John Mathews, Paul J Shaughnessy, Aaron Logan, Abdullah Ladha, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Matthew Connor, Kristen M O'Dwyer, LaQuisa C. Hill, Stephanie B. Tsai, Joshua P Sasine, Melhem M Solh, Catherine J Lee, Vamsi Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Caspian Oliai, Jessica T. Leonard, Noelle V Frey, Jae H. Park, Marlise R. Luskin, Veronika Bachanova, Ahmed Galal, Michael R Bishop, Wendy Stock, Ryan D. Cassaday, Vinod A Pullarkat, Bijal D Shah, Lori Muffly

Blood Adv bloodadvances.2024013747.

https://doi.org/10.1182/bloodadvances.2024013747

Published: 2024

Includes: Supplemental data

Journal Articles

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

James N. Gerson, Elizabeth Handorf, Diego Villa, Alina S. Gerrie, Parv Chapani, Shaoying Li, L. Jeffrey Medeiros, Michael Wang, Jonathon B. Cohen, Michael Churnetski, Brian T. Hill, Yazeed Sawalha, Francisco J. Hernandez-Ilizaliturri, Shalin Kothari, Julie M. Vose, Martin Bast, Timothy Fenske, Swapna Narayana Rao Gari, Kami J. Maddocks, David Bond, Veronika Bachanova, Bhaskar Kolla, Julio Chavez, Bijal Shah, Frederick Lansigan, Timothy Burns, Alexandra M. Donovan, Nina Wagner-Johnston, Marcus Messmer, Amitkumar Mehta, Jennifer K. Anderson, Nishitha Reddy, Alexandra E. Kovach, Daniel J. Landsburg, Martha Glenn, David J. Inwards, Kay Ristow, Reem Karmali, Jason B. Kaplan, Paolo F. Caimi, Saurabh Rajguru, Andrew Evens, Andreas Klein, Elvira Umyarova, Bhargavi Pulluri, Jennifer E. Amengual, Jennifer K. Lue, Catherine Diefenbach, Richard I. Fisher, Stefan K. Barta

Blood Adv (2023) 7 (24): 7393–7401.

https://doi.org/10.1182/bloodadvances.2023010757

Published: 2023

Includes: Supplemental data

Journal Articles

Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era

Blood Adv (2023) 7 (23): 7295–7303.

https://doi.org/10.1182/bloodadvances.2023011205

Published: 2023

Includes: Supplemental data

Journal Articles

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Blood Adv (2023) 7 (18): 5579–5585.

https://doi.org/10.1182/bloodadvances.2023010302

Published: 2023

Includes: Supplemental data

Journal Articles

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Shakthi T. Bhaskar, Vivek G. Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R. Bishop, Joseph P. McGuirk, Richard T. Maziarz, Andy I. Chen, Veronika Bachanova, Joseph E. Maakaron, Peter A. Riedell, Olalekan O. Oluwole

Blood Adv (2023) 7 (17): 4765–4772.

https://doi.org/10.1182/bloodadvances.2022008937

Published: 2023

Journal Articles

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions

Blood Adv (2023) 7 (16): 4528–4538.

https://doi.org/10.1182/bloodadvances.2023010016

Published: 2023

Includes: Supplemental data

Journal Articles

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Kitsada Wudhikarn, Ana Alarcon Tomas, Jessica R. Flynn, Sean M. Devlin, Jamie Brower, Veronika Bachanova, Loretta J. Nastoupil, Joseph P. McGuirk, Richard T. Maziarz, Olalekan O. Oluwole, Stephen J. Schuster, David L. Porter, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales

Blood Adv (2023) 7 (13): 3192–3198.

https://doi.org/10.1182/bloodadvances.2022008294

Published: 2023

Includes: Supplemental data

Journal Articles

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Blood Adv (2023) 7 (11): 2287–2296.

https://doi.org/10.1182/bloodadvances.2022009225

Published: 2023

Includes: Supplemental data

Journal Articles

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

Blood Adv (2021) 5 (23): 5179–5189.

https://doi.org/10.1182/bloodadvances.2021004765

Published: 2021

Includes: Supplemental data

Journal Articles

Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma

Blood Adv (2021) 5 (6): 1648–1659.

https://doi.org/10.1182/bloodadvances.2020003556

Published: 2021

Includes: Supplemental data

Journal Articles

Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor

Blood Adv (2020) 4 (7): 1284–1295.

https://doi.org/10.1182/bloodadvances.2019001259

Published: 2020

Includes: Supplemental data

Journal Articles

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma

Blood Adv (2020) 4 (4): 629–637.

https://doi.org/10.1182/bloodadvances.2019001026

Published: 2020

Includes: Supplemental data

Journal Articles

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia

Sarah Cooley, Fiona He, Veronika Bachanova, Gregory M. Vercellotti, Todd E. DeFor, Julie M. Curtsinger, Paul Robertson, Bartosz Grzywacz, Kevin C. Conlon, Thomas A. Waldmann, David H. McKenna, Bruce R. Blazar, Daniel J. Weisdorf, Jeffrey S. Miller

Blood Adv (2019) 3 (13): 1970–1980.

https://doi.org/10.1182/bloodadvances.2018028332

Published: 2019

Includes: Supplemental data

Journal Articles

Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL

Martin Felices, Behiye Kodal, Peter Hinderlie, Michael F. Kaminski, Sarah Cooley, Daniel J. Weisdorf, Daniel A. Vallera, Jeffrey S. Miller, Veronika Bachanova

Blood Adv (2019) 3 (6): 897–907.

https://doi.org/10.1182/bloodadvances.2018029371

Published: 2019

Includes: Supplemental data

Journal Articles

The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia

Blood Adv (2019) 3 (4): 670–680.

https://doi.org/10.1182/bloodadvances.2018027003

Published: 2019

Journal Articles

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

Blood Adv (2018) 2 (8): 933–940.

https://doi.org/10.1182/bloodadvances.2018018531

Published: 2018

Includes: Supplemental data

NARROW

Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma

Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia

Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL

The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only